Covered recipient · General Payments record
KATHY LOO
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2023–2024
$819.18
- Reported across 21 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $737.23 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $421.44 | 9 |
| Esperion Therapeutics, Inc. | $116.58 | 1 |
| GENZYME CORPORATION | $89.88 | 1 |
| Acerta Pharma LLC | $38.94 | 2 |
| Amgen Inc. | $28.98 | 2 |
| SHIELD THERAPEUTICS INC | $27.87 | 1 |
| Azurity Pharmaceuticals, Inc. | $13.54 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $13.89 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117613683 | CMS |
| Amgen Inc. | $15.09 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117613685 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.88 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104275477 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.06 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105840953 | CMS |
| Azurity Pharmaceuticals, Inc. | $13.54 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134019160 | CMS |
| Esperion Therapeutics, Inc. | $116.58 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129471238 | CMS |
| GENZYME CORPORATION | $89.88 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140004930 | CMS |
| Novo Nordisk Inc | $21.09 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100351182 | CMS |
| Novo Nordisk Inc | $0.32 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100558401 | CMS |
| Novo Nordisk Inc | $121.81 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100343824 | CMS |
| Novo Nordisk Inc | $1.71 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100261091 | CMS |
| Novo Nordisk Inc | $15.97 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100569904 | CMS |
| Novo Nordisk Inc | $87.20 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100532851 | CMS |
| Novo Nordisk Inc | $20.87 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100368469 | CMS |
| Novo Nordisk Inc | $121.81 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100444505 | CMS |
| Novo Nordisk Inc | $30.66 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100314980 | CMS |
| SHIELD THERAPEUTICS INC | $27.87 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150150917 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.